The effect of vigabatrin (γ-vinyl GABA) on cerebral blood flow and metabolism

Neurology

Volumn 53, Issue 7, 1999, Pages 1518-1522

  Spanaki, M V ^a   Siegel, H ^a   Kopylev, L ^b   Fazilat, S ^a   Dean, A ^a   Liow, K ^a   Ben Menachem, E ^c   Gaillard Md, W D ^a,d   Theodore, W H ^a,b  

^a Epilepsy Research Branch   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Cerebral blood flow; Cerebral metabolism; Epilepsy; GABA; PET; Vigabatrin

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; BENZODIAZEPINE RECEPTOR; CARBAMAZEPINE; FLUORODEOXYGLUCOSE F 18; GLUCOSE; OXYGEN 15; PHENOBARBITAL; PHENYTOIN; PLACEBO; VALPROIC ACID; VIGABATRIN;

ADULT; ARTICLE; BRAIN BLOOD FLOW; BRAIN METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG MIXTURE; EPILEPSY; FEMALE; GLUCOSE METABOLISM; HUMAN; MALE; ORAL DRUG ADMINISTRATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032738837     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.7.1518     Document Type: Article

References (40)

1. MacDonald RL, Schulz DW. Barbiturate enhancement of GABA-mediated inhibition and activation of chloride ion conductance: correlation with anticonvulsant and anesthetic actions. Brain Res 1981;209:177-188.
2. Heyer ES, MacDonald RL. Barbiturate reduction of calcium-dependent action potentials: correlation with anesthetic action. Brain Res 1982;236:157-171.
3. Crane PD, Braun LD, Cornford EM, Cremer JE, Glass JM, Oldendorf WH. Dose-dependent reduction of glucose utilization by phenobarbital in rat brain. Stroke 1978;9:12-18.
4. Theodore WH, DiChiro G, Margolin R, Fishbein D, Porter R, Brooks R. Barbiturates reduce human cerebral glucose metabolism. Neurology 1986;36:60-64.
5. Theodore WH. Antiepileptic drugs and cerebral glucose metabolism. Epilepsia 1988;29(suppl 2):S48-S55.
6. Vining EPG, Mellits ED, Dorsen MM, et al. Psychologic and behavioral effects of antiepileptic drugs in children: a double-blind comparison between phenobarbital and valproic acid. Pediatrics 1987;80:165-174.
7. Woodbury DM, Kemp JM. Pharmacology and mechanisms of action of diphenylhydantoin. Psychiatr Neurol Neurochir 1971;74:91-117.
8. McLean MJ, MacDonald RL. Carbamazepine and 10,11-epoxycarbamazepine produce use- and voltage-dependent limitation of rapidly firing action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986;228:727-738.
9. Theodore WH, Bairamian D, Newark ME, et al. Effect of phenytoin on human cerebral glucose metabolism. J Cereb Blood Flow Metab 1986;6:315-320.
10. Theodore WH, Bromfield E, Onorati L. The effect of carbamazepine on cerebral glucose metabolism. Ann Neurol 1989;25: 516-520.
11. Thompson PJ, Trimble MR. Anticonvulsant drugs and cognitive functions. Epilepsia 1982;23:531-544.
12. Trimble MR. Anticonvulsant drugs and cognitive function: a review of the literature. Epilepsia 1987;28(suppl 3):S37-S45.
13. Loscher W. Valproate-induced changes in GABA metabolism at the subcellular level. Biochem Pharmacol 1981;30:1363-1366.
14. McLean MJ, MacDonald RL. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high-frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986; 237:1001-1011.
15. 15O water positron emission tomography study. Epilepsia 1996;37:515-521.
16. Jung MJ, Lippert B, Metcalf BW, Bohlen P, Schechter PJ. γ-vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J Neurochem 1977;29:797-802.
17. Ben-Menachem E, Persson LI, Schechter PJ, et al. Effects of single doses of vigabatrin on CSF concentrations of GABA, homocarnosine, homovanillic acid and 5-hydroxyindoleacetic acid in patients with complex partial epilepsy. Epilepsy Res 1988;2:96-101.
18. Pericic D. Effects of γ-vinyl GABA on the enzymes of GABA system in specific brain regions. Period Biol 1980;82:19-23.
19. Ring HA, Heller AJ, Farr IN, Reynolds EH. Vigabatrin: rational treatment for chronic epilepsy. J Neurol Neurosurg Psychiatry 1990;53:1051-1055.
20. MacDonald RL, Barker JL. Anticonvulsant and anesthetic barbiturates: different postsynaptic actions in cultured mammalian neurons. Neurology 1979;29:432-447.
21. Foster NL, VanDerSpek AFL, Aldrich MS, et al. The effect of diazepam sedation on cerebral glucose metabolism in Alzheimer's disease as measured using positron emission tomography. J Cereb Blood Flow Metab 1987;7:415-420.
22. Kelly PAT, McCulloch J Effects of the putative GABAergic agonists, muscimol and THIP, upon local cerebral glucose utilization. J Neurochem 1982;39:613-624.
23. Palacios JM, Kuhar MJ, Rapoport SI, London ED. Effects of γ-aminobutyric acid agonist and antagonist drugs on local cerebral glucose utilization. J Neurosci 1982;2:853-860.
24. Roland PE, Frinberg L. The effect of the GABA-A agonist THIP on regional cortical blood flow in humans: a new test of hemispheric dominance. J Cereb Blood Flow Metab 1988;8: 314-323.
25. Simler S, Ciesielski L, Maitre M, Randrianarisoa H, Mandel P. Effect of sodium n-dipropylacetate on audiogenic seizure and brain aminobutyric acid level. Biochem Pharmacol 1973; 22:1701-1708.
26. Loscher W. GABA in plasma and cerebrospinal fluid of different species: effects of γ-acetylenic GABA, γ-vinyl GABA and sodium valproate. J Neurochem 1979;32:1587-1591.
27. Rogawski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 1990;42:223-286.
28. Loscher W. Development of tolerance to the anticonvulsant effect of GABAmimetic drugs in genetically epilepsy-prone gerbils. Pharmacol Biochem Behav 1985;24:1007-1013.
29. Ben-Menachem E, Persson LI, Schechter PJ, et al. The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients. Br J Clin Pharmacol 1989;27:79S-85S.
30. Palfreyman MG, Huot S, Grove J Total GABA, homocarnosine in CSF as indices of brain GABA concentrations. Neurosci Lett 1983;35:161-166.
31. Petroff OAC, Rothman DL, Behar KL, Collins TL, Mattson RH. Human brain GABA levels rise rapidly after initiation of vigabatrin therapy. Neurology 1996;47:1567-1571.
32. Ben-Ari Y, Khazipov R, Leinekugel X, Caillard O, Gaiarsa JL. GABAA, NMDA, AMPA receptors: a developmentally regulated 'menage a trois.' Trends Neurosci 1997;20:523-529.
33. Loscher W. Effects of inhibitors of GABA transaminase on synthesis binding uptake and metabolism of GABA. J Neurochem 1980;34:1603-1608.
34. Jackson MF, Dennis T, Esplin B, Capek R. Acute effects of γ-vinyl GABA (vigabatrin) on hippocampal GABAergic inhibition in vitro. Brain Res 1994;651:85-91.
35. Chase TN, Fedio P, Foster NL, Brooks R, Di Chiro G, Mansi L. Wechsler Adult Intelligence Scale performance: cortical localization by fluorodeoxyglucose F 18-positron emission tomography. Arch Neurol 1984;41:1244-1247.
36. Rausch R, Henry TH, Ary CM, Engel J Jr, Mazziotta J. Asymmetric interictal glucose metabolism and cognitive performance in epileptic patients. Arch Neurol 1994;51:139-144.
37. Reynolds EH, Travers RD. Serum anticonvulsant concentrations in epileptic patients with mental symptoms. Br J Psychiatry 1974;124:440-445.
38. Meador KJ, Loring DW, Moore EE, et al. Comparative cognitive effects of phenobarbital, phenytoin, and valproate in healthy adults. Neurology 1995;45:1494-1499.
39. McGuire AM, Duncan JS, Trimble MR. Effects of vigabatrin on cognitive function and mood used as add-on therapy in patients with intractable epilepsy. Epilepsia 1992;33:128-134.
40. Dodrill CB, Arnett JL, Sommerville KW, Sussman NM. Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology 1993;43:2501-2507.